• C J Turtle, S R Riddell, and D G Maloney.
• Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
• Clin. Pharmacol. Ther. 2016 Sep 1; 100 (3): 252-8.

AbstractChimeric antigen receptors (CARs) comprise a tumor-targeting moiety, often in the form of a single chain variable fragment derived from a monoclonal antibody, fused to one or more intracellular T-cell signaling sequences. Lymphodepletion chemotherapy followed by infusion of T cells that are genetically modified to express a CD19-specific CAR is a promising therapy for patients with refractory CD19(+) B-cell malignancies, producing rates of complete remission that are remarkably high in acute lymphoblastic leukemia and encouraging in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Responses are often durable, although additional studies are needed to define the role of CAR-T cell immunotherapy in the context of other treatments. CAR-modified T-cell immunotherapy can be complicated by cytokine release syndrome and neurologic toxicity, which in most cases are manageable and reversible. Here we review recent clinical trial data and discuss issues for the field.© 2016 American Society for Clinical Pharmacology and Therapeutics.

26 keywords...

hide…